

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/Caplus updated with revised CAS roles
NEWS	7	JAN 22	CA/Caplus enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	26	APR 30	CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS	27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	28	MAY 01	New CAS web site launched
NEWS	29	MAY 08	CA/Caplus Indian patent publication number format defined
NEWS	30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:29:32 ON 17 MAY 2007

=> File .Gerry1

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'BIOSIS' ENTERED AT 12:29:48 ON 17 MAY 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 12:29:48 ON 17 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:29:48 ON 17 MAY 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:29:48 ON 17 MAY 2007

=> S anti-BAG(S) (treatment OR Disease) AND pd<=12/30/2002

3 FILES SEARCHED...

L1 0 ANTI-BAG(S) (TREATMENT OR DISEASE) AND PD<=12/30/2002

=> S anti-BAG(S) (treatment OR Disease)

L2 0 ANTI-BAG(S) (TREATMENT OR DISEASE)

=> S BAG(3A) antibody(S) (treatment OR Disease)

L3 6 BAG(3A) ANTIBODY(S) (TREATMENT OR DISEASE)

=> Dup Rem L3

PROCESSING COMPLETED FOR L3

L4 6 DUP REM L3 (0 DUPLICATES REMOVED)

=> D Ibib Abs L41-6

'L999-998' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):Ibib Abs L4 1-6

'L16' IS NOT A VALID FORMAT

'1-6' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):1

'1' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):L4

'L16' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):Ibib

L4 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
 ACCESSION NUMBER: 2007:245401 BIOSIS  
 DOCUMENT NUMBER: PREV200700246504  
 TITLE: In multiple myeloma (MM) CAMPATH-1 antibodies "in the bag" reduce the early toxicity of stem cell transplantation from graft vs. host disease (GvHD) and seem to be associated with improved long term outcome.  
 AUTHOR(S): Novitzky, Nicolas [Reprint Author]; Thomas, Valda; du Toit, Cecile  
 CORPORATE SOURCE: Univ Cape Town, Groote Schuur Hosp Observatory, Dept Haematol, ZA-7925 Cape Town, South Africa  
 SOURCE: Blood, (NOV 16 2006) Vol. 108, No. 11, Part 2, pp. 433B. Meeting Info.: Symposium of the International-Society-of-Molecular-Evolution. GUANANACASTE, COSTA RICA. January 08 -12, 2001. Int Soc Molec Evolut. CODEN: BLOOAW. ISSN: 0006-4971.  
 DOCUMENT TYPE: Conference; (Meeting)  
 Conference; Abstract; (Meeting Abstract)  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 18 Apr 2007  
 Last Updated on STN: 18 Apr 2007

=> D ibib ABS L4 2-5

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:523755 CAPLUS  
 DOCUMENT NUMBER: 143:38367  
 TITLE: Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases  
 INVENTOR(S): Multhoff, Gabriele  
 PATENT ASSIGNEE(S): Multimmune G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 84 pp. CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054868	A1	20050616	WO 2004-EP13858	20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1695093	A1	20060830	EP 2004-819661	20041206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRIORITY APPLN. INFO.:			EP 2003-28143	A 20031205
			WO 2004-EP13858	W 20041206
AB Methods and compns. for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are provided. In particular, the detection, prevention and treatment of infectious diseases and cancer mediated and/or indicated by the presence and co-localization of a member of the anti-apoptotic Bcl-2-associated athanogene				

(Bag) family, especially Bag4 and membrane-bound heat shock protein (Hsp) on the cell surface of diseased tissue or cells are described. The expts. according to the present invention have shown that membrane-bound Hsp70/Bag-4 prevents tumor cells from irradiation-induced effects. Therefore, Hsp70/Bag-4 membrane expression is expected to be useful as a prognostic marker and target for therapy-resistant tumor cell clones. In addition, evidence is provided for Hsp70/Bag-4 as a target recognition structure for NK cell-mediated cytotoxicity.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2005:506033 BIOSIS

DOCUMENT NUMBER: PREV200510301698

TITLE: HGF/SF stimulates the proliferation of lens epithelial cells through MAPK signaling.

AUTHOR(S): Choi, J. [Reprint Author]; Park, S.; Joo, C.-K.

CORPORATE SOURCE: Catholic Univ Korea, Dept Ophthalmol and Visual Sci, Seoul, South Korea

SOURCE: IOVS, (APR 2004) Vol. 45, No. Suppl. 1, pp. U705. Meeting Info.: Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology. Ft Lauderdale, FL, USA. April 24 -29, 2004. Assoc Res Vis & Ophthalmol. CODEN: IOVSDA. ISSN: 0146-0404.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 23 Nov 2005

Last Updated on STN: 23 Nov 2005

AB Purpose: Posterior capsule opacification (PCO) is caused by proliferation and migration of lens epithelial cells remained after cataract surgery. It has been known that the various cytokines are involved in the proliferation of lens epithelial cells. In this study, we investigated the role of HGF in lens epithelial cells and the signaling pathways that contribute to HGF-induced proliferation. Methods: Capsular-bags prepared from porcine eyes were maintained in serum-free DMEM. The human lens epithelial B3 cells (HLE B3) and rat lens epithelial explants were cultured in MEM supplemented with 20% FCS and Medium 199 with Earle's salts supplemented with 0.1% BSA, respectively. The cell proliferation was determined by MTT assay, PCNA expression or flow cytometric analysis. The antisense oligonucleotide was used to inhibit the cyclin D1 expression. Activation of MAPKs and PI3K pathway was detected by western blot analysis. Results: HGF induced the proliferation of lens epithelial cells and HGF-stimulated proliferation was significantly inhibited by the treatment with neutralizing c-Met antibody in capsular-bag culture. Studies of the signaling pathway used by HGF in lens epithelial cells to induce proliferation revealed that HGF activates the MAP kinases, ERK and JNK/SAPK, but not p38. Activation of both ERK and JNK/SAPK is required for the HGF-stimulated induction of cyclin D1, which is necessary for the HGF-induced proliferation of lens epithelial cells. PI3K also participated in the regulation of cyclin D1 expression as the upstream of ERK and JNK/SAPK. Conclusions: Taken together, our data indicate that HGF may be a potent growth factor for the lens epithelial cells and contribute the development of PCO, and suggest that the signaling pathway involved in HGF-stimulated proliferation is a potential therapeutic target for PCO.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:220790 CAPLUS

DOCUMENT NUMBER: 136:229602

TITLE: BAG proteins of Arabidopsis thaliana and their use in delaying senescence and improving disease and stress resistance in transgenic plants

INVENTOR(S): Dickman, Martin B.

PATENT ASSIGNEE(S): The Board of Regents of the University of Nebraska,  
USA  
SOURCE: PCT Int. Appl., 86 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022822	A2	20020321	WO 2001-US29169	20010914
WO 2002022822	A3	20030807		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002116734	A1	20020822	US 2001-946805	20010904
AU 2001091081	A5	20020326	AU 2001-91081	20010914
PRIORITY APPLN. INFO.: US 2000-232566P P 20000914				
US 2001-946805 A 20010904				
WO 2001-US29169 W 20010914				

AB This invention provides isolated BAG polypeptides namely BAG-1, BAG-2, BAG-3 and BAG-4 of Arabidopsis thaliana and functional fragments thereof as well as genes encoding the same. Methods utilizing BAG polypeptides or functional fragments thereof, to modulate cell apoptosis in transgenic plants or transgenic plant cells are provided. These methods may be used to delay senescence in transgenic plants and to improve disease and stress resistance. More specifically, insect, plant, fungus, nematode, bacterial or viral resistance is improved in plants encoding BAG proteins. Also, resistance of transgenic plants to moisture, salinity, nutrient deficiency, air pollution, temperature, soil toxicity, herbicides, insecticides or other stress conditions is also provided. BAG proteins are capable of interacting with apoptotic pathway proteins like caspase, rev-caspase, Bcl-2 and other related proteins, Apaf-1, Bad, Bax, Ced-9, Ced-4 and HSP70. Antibodies for detection of BAG proteins as methods of screening for modulators of BAG protein binding by contacting BAG proteins with an agent are also provided in the present invention.

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:239419 CAPLUS  
DOCUMENT NUMBER: 136:353939  
TITLE: Bag-1 up-regulation in anti-CD4 mAb treated allo-activated T cells confers resistance to apoptosis  
AUTHOR(S): Sawitzki, Birgit; Lehmann, Manfred; Vogt, Katrin; Risch, Kirsten; Brock, Josef; Kupiec-Weglinski, Jerzy W.; Volk, Hans-Dieter  
CORPORATE SOURCE: Nuffield Department of Surgery, John Radcliffe Hospital, Oxford University, Oxford, UK  
SOURCE: European Journal of Immunology (2002), 32(3), 800-809  
CODEN: EJIMAF; ISSN: 0014-2980  
PUBLISHER: Wiley-VCH Verlag GmbH  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The nondepleting anti-CD4 mAb RIB5/2 is a powerful inducer of tolerance to MHC-incompatible renal and heart allografts in rat recipients. In vitro the mAb blocks the proliferation and cytokine production of alloreactive T cells. To learn more about the mechanism of anti-CD4-mediated suppression, the authors applied differential display reverse

transcription-PCR to identify differences at mRNA level between T cells stimulated by alloantigen in the presence or absence of anti-CD4 mAb. A sequence alignment of a 550-bp DNA fragment appearing only in anti-CD4 mAb-treated cells resulted in at least 95% homol. to a mouse cDNA encoding for the anti-apoptotic protein Bag-1. Further investigation of Bag-1 expression during mixed lymphocyte reactions revealed a three- to fourfold up-regulation of Bag-1 mRNA expression in anti-CD4 mAb-treated allogeneic cultures which was confirmed at protein level. Bag-1 up-regulation was associated with an increase resistance to apoptosis of T cells from anti-CD4 mAb-treated cultures. Application of antisense oligonucleotides specific for Bag-1 reduced Bag-1 protein expression and restored susceptibility to apoptosis. In addition, up-regulation of Bag-1 mRNA could also be detected in graft-infiltrating T cells from anti-CD4 mAb-treated rats in vivo. Thus, the expression of Bag-1 in a subset of anti-CD4 mAb-treated alloreactive T cells conferred resistance against apoptosis, potentially contributing to the long-term survival of these cells.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> Log off h

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:36:37 ON 17 MAY 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE'  
AT 12:40:39 ON 17 MAY 2007  
FILE 'BIOSIS' ENTERED AT 12:40:39 ON 17 MAY 2007  
Copyright (c) 2007 The Thomson Corporation  
FILE 'CAPLUS' ENTERED AT 12:40:39 ON 17 MAY 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)  
FILE 'EMBASE' ENTERED AT 12:40:39 ON 17 MAY 2007  
Copyright (c) 2007 Elsevier B.V. All rights reserved.  
FILE 'MEDLINE' ENTERED AT 12:40:39 ON 17 MAY 2007

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	47.46	47.67
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

=> D Hist

(FILE 'HOME' ENTERED AT 12:29:32 ON 17 MAY 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE' ENTERED AT 12:29:48 ON 17 MAY 2007

L1 0 S ANTI-BAG(S) (TREATMENT OR DISEASE) AND PD<=12/30/2002  
L2 0 S ANTI-BAG(S) (TREATMENT OR DISEASE)  
L3 6 S BAG(3A) ANTIBODY(S) (TREATMENT OR DISEASE)  
L4 6 DUP REM L3 (0 DUPLICATES REMOVED)

=> S (Bcl-2-associated protein) (3A) ANTIBODY(S) (TREATMENT OR DISEASE)  
L5 0 (BCL-2-ASSOCIATED PROTEIN) (3A) ANTIBODY(S) (TREATMENT OR DISEASE)

=> Log off y

STN INTERNATIONAL LOGOFF AT 12:43:35 ON 17 MAY 2007

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5	"6696558"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2007/05/17 16:02
L2	5	"5652223"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2007/05/17 16:02